291 4.Aspetti clinici ed assistenziali trasversali Bibliografia [1] Gasparro FP, Dall'Amico R, Goldminz D, et al. Molecular aspects of photopheresis. Yale J Biol Med. 1989; 62: 579-93 [2] Yoo EK, Rook AH, et al. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 1996; 107: 235-42 [3] Edelson R, Photopheresis: a clinically relevantimmunobiologic response modifier. Ann NY Acad Sci. 1991; 636: 154-64 [4] Schooneman F. Extracorporeal photophoresis technical aspects. Transfusion Apher Sci. 2003; 28: 51-61 [5] Schwartz J, Padmanabhan A, Aqui N. et al. Guidelines on the use of therapeutic apheresis in clinical pratice – evidence-based approach from the writing committee of the American Society for the Apheresis: the seventh special issue. J Clin Apheresis 2016 (31): 149-162 [6] Perseghin P. Extracorporeal photochemotherapy as a challenging treatment for cutaneous T-cell lymphoma, acute and chronic graft-versus-host-disease, organ rejection and T-lymphocyte-mediated autoimmune diseases. Transfus Med Hemother 2008: 35; 8-17 [7] Bladon J, Taylor PC. Extracorporeal photopheresis: a focus on apoptosis and cytokines. J. Dermatol. Sci. 2006;43(2):85–94 [8] Morison WL, Parrish JA, McAuliffe DJ, Bloch KJ. Sensitivity of mononuclear cells to PUVA: effect on subsequent stimulation with mitogens and on exclusion of trypan blue dye. Clin. Exp. Dermatol. 1981;6(3):273–7 [9] Berger CL, Hanlon D, Kanada D, Girardi M, Edelson RL. Transimmunization, a novel approach for tumor immunotherapy. Transfus. Apher. Sci. 2002;26(3):205–16 [10] Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood. 2002;100(3):941–7 [11] Alcindor T, Gorgun G, Miller KB, et al. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood. 2001;98(5):1622–5 [12] Franklin C, Cesko E, Hillen U, Schilling B, Brandau S. Modulation and Apoptosis of Neutrophil Granulocytes by Extracorporeal Photopheresis in the Treatment of Chronic Graft-Versus-Host Disease. PLoS One. 2015;10(8):e0134518 [13] Franklin C, Cesko E, Hillen U, Schilling B, Brandau S. Modulation and Apoptosis of Neutrophil Granulocytes by Extracorporeal Photopheresis in the Treatment of Chronic Graft-Versus-Host Disease. PLoS One. 2015;10(8):e0134518 [14] Rieber N, Wecker I, Neri D, et al. Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD. Bone Marrow Transplant. 2014;49(4):545–52 [15] Mankarious M, Matthews NC, Snowden JA, Alfred A. Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD). Front. Immunol. 2020;11:81 [16] Pratta M, Paczesny S, Socie G, et al. A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease. Br. J. Haematol. 2022 [17] Major-Monfried H, Renteria AS, Pawarode A, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131(25):2846–2855 [18] Adom D, Rowan C, Adeniyan T, Yang J, Paczesny S. Biomarkers for Allogeneic HCT Outcomes. Front. Immunol. 2020;11:673 [19] Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990;76(October (8)):1464–72 [20] Das - Gupta E, Dignan F, Shaw B, Raj K, Malladi R, Gennery A, et al. Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literature. Bone Marrow Transplant 2014;49 (10):1251–8 [21] Wolff D, Schleuning M, von Harsdorf S et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: 1–17 [22] Wolff D, Gerbitz A, Ayuk F et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010; 16: v1611–1628 [23] Greinix HT, Socie G, Bacigalupo A et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant 2006; 38: 265–273 [24] Malik MI, Litzow M, Hogan W, Patnaik M, Murad MH, Prokop LJ, et al. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res. 2014 Jun;49(2):100–6 [25] Greinix HT, van Besien K, Elmaagacli AH, Hillen U, Grigg A, Knobler R, et al.; UVADEX Chronic GVHD Study Group. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis—results of a crossover randomized study. Biol Blood Marrow Transplant. 2011 Dec;17(12):1775–82 [26] Jagasia M, Scheid C, Socié G, Ayuk FA, Tischer J, Donato ML, et al. Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD. Blood Adv. 2019 Jul;3(14):2218–29 [27] Sestili S, Eder S, Belhocine R, Dulery R, et al. Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience.Cytotherapy. 2020 Aug;22(8):445-449 [28] Pierelli L., Perseghin P., Marchetti M, et al. Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host-disease in adults and children: best practice recommendations from Italian Society of hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. Transfusion 2013 Jan10, dopi:10.111/trf 12059 [29]Drexler B, Buser A, Infanti L, et al. Extracorporeal Photopheresis in Graft-versus-Host Disease. Transfus. Med. Hemother. 2020;47(3):214–225 [30] Golestaneh L., Mokrzycki MH. Vascular access in therapeutic apheresis: update. J Clin Apher 2013; 28(1): 64-72
RkJQdWJsaXNoZXIy ODUzNzk5